other material
confidence high
sentiment positive
materiality 0.65
First Tracks Biotherapeutics raises $200M in private placement at $32.75/share
First Tracks Biotherapeutics, Inc.
- Sells 6,106,870 common shares at $32.75/share for ~$200M gross proceeds; closing expected October 19, 2026, subject to customary conditions.
- Investors include Affinity Asset Advisors, First Light Asset Management, Sirenia Capital, TCGX, Trails Edge Capital, Vestal Point Capital and mutual funds.
- Proceeds intended for general corporate purposes, including clinical development of ANB033, a CD122 antagonist.
- Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities acted as placement agents.
- Shares issued under Section 4(a)(2); resale registration statement due within 30 days of closing. 35,909,814 shares outstanding as of Oct 12, 2026.